Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
In development [GID-TA10751] Expected publication date: TBC
Search results
680 results
-
-
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]
In development [GID-TA10387] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]
In development [GID-TA10739] Expected publication date: 25 May 2022
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]
In development [GID-TA10827] Expected publication date: 14 December 2021
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 05 January 2022
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: TBC
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: TBC
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
In development [GID-TA10666] Expected publication date: 26 August 2021
-
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
In development [GID-TA10618] Expected publication date: TBC
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
In development [GID-TA10658] Expected publication date: 20 October 2021
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
In development [GID-TA10706] Expected publication date: 20 October 2021
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
In development [GID-TA10719] Expected publication date: 02 February 2022
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]
In development [GID-TA10782] Expected publication date: 20 October 2021
-
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]
In development [GID-TA10260] Expected publication date: TBC
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Ponesimod for treating relapsing multiple sclerosis [ID1393]
In development [GID-TA10556] Expected publication date: 17 November 2021
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]
In development [GID-TA10209] Expected publication date: TBC
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: 25 August 2021
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: TBC
-
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
In development [GID-TA10451] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: 25 May 2022
-
Lasmiditan for treating acute migraine [ID3759]
In development [GID-TA10807] Expected publication date: 29 March 2023
-
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
In development [GID-TA10305] Expected publication date: TBC
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]
In development [GID-TA10510] Expected publication date: 28 April 2021
-
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: 28 April 2021
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
In development [GID-TA10808] Expected publication date: 05 January 2022
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: TBC
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: 30 June 2021
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-TA10690] Expected publication date: TBC
-
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: TBC